BR112016022819A2 - uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo - Google Patents

uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo

Info

Publication number
BR112016022819A2
BR112016022819A2 BR112016022819A BR112016022819A BR112016022819A2 BR 112016022819 A2 BR112016022819 A2 BR 112016022819A2 BR 112016022819 A BR112016022819 A BR 112016022819A BR 112016022819 A BR112016022819 A BR 112016022819A BR 112016022819 A2 BR112016022819 A2 BR 112016022819A2
Authority
BR
Brazil
Prior art keywords
human
cross
cinomolgus
antibody
reactive antibody
Prior art date
Application number
BR112016022819A
Other languages
English (en)
Portuguese (pt)
Inventor
Jaeger Christiane
Moessner Ekkehard
Tiefenthaler Georg
Platzer Josef
Ritter Mirko
Offner Sonja
Lifke Valeria
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016022819A2 publication Critical patent/BR112016022819A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112016022819A 2014-05-28 2015-05-22 uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo BR112016022819A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170140 2014-05-28
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (1)

Publication Number Publication Date
BR112016022819A2 true BR112016022819A2 (pt) 2018-01-16

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022819A BR112016022819A2 (pt) 2014-05-28 2015-05-22 uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo

Country Status (13)

Country Link
US (3) US20170233475A1 (enExample)
EP (2) EP3763739A1 (enExample)
JP (1) JP6738285B2 (enExample)
KR (1) KR20170003591A (enExample)
CN (1) CN106459201A (enExample)
AU (1) AU2015266077A1 (enExample)
BR (1) BR112016022819A2 (enExample)
CA (1) CA2942453A1 (enExample)
IL (1) IL247740A0 (enExample)
MX (1) MX2016015389A (enExample)
RU (1) RU2016151235A (enExample)
SG (1) SG11201609950YA (enExample)
WO (1) WO2015181098A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
FI3561057T3 (fi) * 2016-12-22 2025-10-07 Daiichi Sankyo Co Ltd Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3634998B8 (en) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
TWI820041B (zh) * 2017-09-21 2023-11-01 中國大陸商上海藥明生物技術有限公司 新型抗CD3ε抗體
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method
CA3093330A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
MX420253B (es) * 2018-05-24 2025-02-10 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos.
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
IL298444A (en) * 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins containing cd3 antigen binding sites and uses thereof
JP2023542209A (ja) * 2020-09-24 2023-10-05 モルフォシス・アーゲー ヒトｃｄ３イプシロンに結合する新規なヒト抗体
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
EP4314075A4 (en) * 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4329800A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
KR20240158351A (ko) * 2022-03-22 2024-11-04 모르포시스 아게 Cd3에 특이적인 탈면역화 항체
MX2024011468A (es) 2022-03-23 2024-09-25 Hoffmann La Roche Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
AU2023251832A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
DK2155788T3 (da) * 2007-04-03 2012-10-08 Amgen Res Munich Gmbh Krydsartsspecifikke bispecifikke bindemidler
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN107827985A (zh) * 2011-05-21 2018-03-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Also Published As

Publication number Publication date
RU2016151235A3 (enExample) 2019-01-18
RU2016151235A (ru) 2018-06-28
US20200299385A1 (en) 2020-09-24
US20200325224A1 (en) 2020-10-15
KR20170003591A (ko) 2017-01-09
CA2942453A1 (en) 2015-12-03
JP6738285B2 (ja) 2020-08-12
MX2016015389A (es) 2017-04-13
CN106459201A (zh) 2017-02-22
AU2015266077A1 (en) 2016-09-29
SG11201609950YA (en) 2016-12-29
IL247740A0 (en) 2016-11-30
EP3763739A1 (en) 2021-01-13
JP2017516786A (ja) 2017-06-22
US20170233475A1 (en) 2017-08-17
EP3149041A1 (en) 2017-04-05
WO2015181098A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
BR112016022819A2 (pt) uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
CL2021002637A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano y métodos para antagonizar cb1 (divisional de la solicitud no. 201602433)
BR112017021500A2 (pt) terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
BR112016003417A2 (pt) diacorpo otimizado por sequência capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, diacorpo biespecífico capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, composição farmacêutica, e uso da composição farmacêutica
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112019012570A8 (pt) Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo
MX382284B (es) Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes.
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
EA201791270A1 (ru) Модифицированные april-связывающие антитела
BR112017003505A2 (pt) anticorpos e receptores de antígeno quiméricos específicos para cd19
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
UA122528C2 (uk) Сполуки, які модулюють fxr (nr1h4)
EA201890028A1 (ru) Антитело, связывающее cd3 человека
HK1252675A1 (zh) 抗cd33抗体及其使用方法
GEP201706794B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX2016006709A (es) Moduladores de aplnr y usos de estos.
BR112012014975A2 (pt) novos anticorpos antagonistas e seus fragmentos fab contra gpvi e seus usos
WO2016205551A3 (en) Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
BR112016030983A8 (pt) composições para o tratamento de obesidade, prevenção de ganho de peso, promoção de perda de peso, promoção de emagrecimento, ou tratamento de ou prevenção do desenvolvimento de diabetes, kit, método para a preparação de tirfostina 9 e uso
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements